Drug profile

The FDA adverse-event record for Mycophenolate Mofetil

25 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Mycophenolate Mofetil. Species, reactions, and outcomes follow.

#1597 of 2,679
by report volume (all drugs)
25
adverse-event reports
40.0%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Mycophenolate Mofetil ranks #1577 of 2679 by total reports (25). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1577
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Mycophenolate Mofetil has 25 reports now versus 23 in that prior snapshot: 2 more (8.7%).

Report change
+2
Death-coded reports
+0
Death-coded share
−3.5 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Mycophenolate Mofetil changes

Signature read: Mycophenolate Mofetil's 40.0% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
25
Total Reports
10
Deaths Reported
40.0%
Death-coded share of reports

Active Ingredients

Mycophenolate Mofetil

Administration Routes

UnknownOral

Species Affected

Dog 23
Human 2

Most Affected Breeds

Retriever - Labrador 5
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 3
Boxer (German Boxer) 2
Unknown 2
Shepherd Dog - Australian 2
Dog (unknown) 1
Pug 1
Corgi (unspecified) 1
Dachshund - Standard Smooth-haired 1
Terrier (unspecified) 1

Most Reported Reactions

Immune mediated haemolytic anaemia 8
Vomiting 7
Lethargy (see also Central nervous system depression in Neurological) 7
Leucocytosis NOS 6
Thrombocytopenia 6
Death by euthanasia 6
Lethargy (see also Central nervous system depression in 'Neurological') 5
Diarrhoea 5
Neutrophilia 5
Elevated total bilirubin 5
Decreased haematocrit 5
Decreased packed cell volume (PCV) 5

Outcome Breakdown

Ongoing
7 (28.0%)
Euthanized
6 (24.0%)
Outcome Unknown
6 (24.0%)
Died
4 (16.0%)
Recovered/Normal
2 (8.0%)

Mycophenolate Mofetil: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Mycophenolate Mofetil (#1597 of 2,679 by report volume); death-coded 40.0%. PlainBreed drug row · death-coded share stamp 40.0% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →